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ABSTRACT 
Claire C. Neal: Treatment Costs of Pediatric Cancer in Rwanda 
(Under the direction of Sandra Greene)  
Problem: Worldwide, a child is diagnosed with cancer every three minutes.1  More 
than 80% of the approximately 200,000 children diagnosed each year live in low and middle 
income countries.2  All too often these children have little to no access to life-saving care:  
only 20% of children diagnosed have access to effective treatment and 90% of childhood 
cancer deaths now occur in low income countries where access to effective treatment is 
severely limited.2, 3 
Rationale:  Despite these disheartening statistics, childhood cancer can be highly 
curable when access to treatment is available. Dramatic improvements in childhood survival 
rates have been achieved in low income countries where a commitment to access to care 
has been made and long-term partnerships have been established.4   Unfortunately, 
questions around the affordability of cancer care persist.  
Study Design:  The project utilized a micro-costing approach to capture and calculate 
a cost for the overall cancer program at the Butaro Cancer Center of Excellence in Rwanda 
as well as a per patient cost for 2 common pediatric cancers:  Hodgkin lymphoma and 
Wilms’ tumor.  Costs were analyzed retrospectively from the Ministry of Health perspective 
for the fiscal year 2013-2014 and comprised fixed costs, including infrastructure, utilities, 
administrative costs and maintenance costs, as well as variable costs such as drug pricing, 
social support, staff salaries, and patient support costs.  
Results:  The overall cost of the cancer program for the 2013-2014 fiscal year was 
estimated at $953,499 with an additional $556,105 necessary for start-up activities. Over 
the course of the study period 1,290 new patients were enrolled and 1,286 existing patients 
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were treated at an average cost per patient across cancer types of $777. The cost for a full 
course of treatment and follow-up was determined to be $2,036 for a patient with Wilms 
Tumor.  Adjusting for expected outcomes, the cost per patient decreases to $1,432.  The 
cost for a full course of treatment for a pediatric patient with Hodgkin Lymphoma was 
determined to be between $1,147 and $1,744.  The experience of the Butaro Cancer Center 
makes a strong case for the affordability of cancer care in low income settings.  
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CHAPTER ONE:  INTRODUCTION 
BACKGROUND 
Cancer is increasingly a problem in the developing world.  Worldwide, a child is 
diagnosed with cancer every three minutes.1 Currently, more than 80% of the 
approximately 200,000 children diagnosed each year live in low and middle income 
countries.2 
All too often these children have little to no access to life-saving care.  It is estimated 
that only 20% of children diagnosed worldwide have access to effective treatment.3  And in 
fact 90% of childhood cancer deaths now occur in low income countries where access to 
effective treatment is severely limited.2  In sub-Saharan Africa, cancer treatment has been 
shown to be unaffordable for all but the wealthiest of patients.5  As a result, as few as 5% 
of cancer patients receive chemotherapy.6  Even when a child has access to care and is able 
to begin a chemotherapy regimen, they are often forced to interrupt or abandon treatment 
due to problems with affordability over the entire treatment regimen, issues with consistent 
availability of the drugs, or costs associated with poverty such as the confounding costs of 
transportation and lost wages.7  These barriers to care can significantly impact survival 
rates. 
These barriers also take an enormous human and economic toll.  A child dying 
unnecessarily of cancer will lose an average of 67 years, producing a great economic loss 
for a country, and an unspeakable loss for a family.8 Parents will often seek any and all 
means of care available, plunging their families into poverty to save a child’s life, even when 
effective care is not available.  The combination of medical expenses and the loss of income 
that a parent experiences when caring for or trying to locate care for a child with cancer can 
create significant financial problems for the entire household.9  Increasingly, households in 
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low and middle income countries are being forced into poverty (or deeper into poverty) due 
to medical expenses.10  Treatment for non-communicable diseases, such as cancer, often 
result in dramatic shifts in spending patterns, with less money spent on food and education 
and a greater frequency of economic actions associated with distress, such as high risk 
borrowing and liquidation of assets.11 The odds of catastrophic household expenditures for 
hospitalization with cancer are 160% higher than for communicable diseases.11 
Despite these disheartening statistics, childhood cancer can be highly curable when 
access to treatment is available.  Treatment regimens have progressed tremendously for 
many childhood cancers over the last decades: survival rates in the United States have 
increased from approximately 10% fifty years ago to close to 80% today.4  Many pediatric 
cancers (and particularly those most often found in developing countries) are highly curable 
with readily available technology (chemotherapy, surgery, and radiotherapy) and drugs that 
are off patent.  Further, simple and effective treatment regimens have been shown to be 
effective in low income countries.   Regimens that are effective in high income countries are 
not necessarily the same treatment strategies needed in low income settings.  Locally 
adapted protocols that minimize toxicity and length of stay in the hospital (and are 
therefore less expensive than those followed in high income countries) have been shown to 
cure a significant number of children when applied with appropriate social support in low 
resource settings.12,13  Dramatic improvements in childhood survival rates have been 
achieved in low income countries where a commitment to access to care has been made 
and long-term partnerships have been established.4  For example, the French African 
Paediatric Oncology Group (GFAOP) was able to improve survival rates for children with 
Burkitt lymphoma across eight pediatric oncology units in Algeria, Cameroon, Madagascar, 
Morocco, Tunisia, and Senegal in just 3 years from 54% in the first year to 73% in the third 
year.14 
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RATIONALE 
Despite the heavy cancer burden in low-income and middle-income countries and the 
lack of existing infrastructure, only 5% of the world’s resources to fight cancer are spent in 
these countries. 15  Even more disheartening is the fact that in the poorest 25 countries, an 
estimated 90% of children with cancer will die. In countries like Canada and the United 
States, this statistic is almost flipped – only about 20% of children diagnosed with cancer 
will die and 80% will live.16  Why, then, do these staggering health inequities persist despite 
the growing burden in human and economic costs and the availability of well-established, 
relatively simple treatment options?    
Four dominant myths about cancer care and control in the developing world have 
been proposed to explain the perpetuation of this divide.16  The Global Task Force for 
Expanded Access to Cancer Control proposes that cancer control has not been a priority, 
because “cancer care is largely believed to be: 
1. unnecessary because cancer is not a problem in low income countries. 
2. unattainable because low income countries do not have adequate infrastructure 
to handle treatment and care. 
3. inappropriate because resources should only be focused on high burden diseases 
that have proven treatments and interventions. 
4. expensive and unaffordable for most low income countries.” 
The cancer control community has made significant progress in addressing the first 
three myths – necessity, attainability, and appropriateness.  First, while cancer has been 
traditionally viewed as a problem of the elderly, and one affecting only wealthy countries, 
world leaders and policy makers are now beginning to understand the growing burden 
worldwide.  In 1970, only 15 percent of new cancer cases occurred in the developing world. 
Currently, over half of new cancer cases, and almost two-thirds of cancer deaths, occur in 
low-income and middle-income countries.1  
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Second, while cancer was once thought of as too complex to be treated in the 
developing world, we now know that effective models exist and that quality cancer care can 
be delivered in even the most resource-poor settings.  Cancer programs in low income 
countries are now making great strides in developing replicable models for delivering high 
quality cancer care despite few oncologists and low availability of advanced equipment and 
resources.  These advances have largely been made by leveraging existing health systems 
and building capacity that supports multiple specific diseases.  The argument against 
providing cancer care is similar to those that were made in the past against the treatment of 
AIDS and TB in low-resource settings.  The complexity, cost and infrastructure necessary to 
combat these diseases seemed insurmountable to many.  We now know that these barriers 
can be overcome.  Treatment for complex diseases can be adapted to local contexts; and 
high cost variables, such as drug prices, can be successfully negotiated.  The example of 
AIDS medications are particularly instructive, as concerted advocacy efforts and bulk pricing 
were able to reduce medication costs by as much as 90% from the price when introduced in 
high income countries to the price for purchase in low income countries.16   
Finally, while all countries have to make difficult choices as to where to allocate 
resources in response to the unique needs of their population, it is well established that 
children have a fundamental right to care.17  Many low and middle income countries have 
accomplished dramatic reductions in childhood mortality rates due to infectious diseases18; 
as a result, the proportion of children dying from non-communicable diseases in these 
countries is growing19.  Childhood cancers are not connected with life-style factors or 
environmental exposures and are therefore not amenable to population-based screening 
and prevention programs; reducing mortality requires effective treatment20.   This life-
saving treatment can be delivered by leveraging existing infrastructure.  The either/or 
dichotomy represented by the argument that it is inappropriate to treat cancer in these 
settings ignores both the growing burden and the growing solutions available in these 
countries.    
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Because of the efforts made by the cancer control community to overcome these 
myths, we are beginning to see a shifting tide in the policy realm with regard to the need, 
feasibility and appropriateness of cancer care in low resource settings.  However, questions 
around the affordability of cancer care continue to pose problems.  The field has made some 
strides in recognizing the costs of inaction, in terms of lost productivity, ties to poverty and 
burden on the health system.21  However, models for delivering care are still relatively new 
and the costs of high quality cancer care in low resource settings have not yet been well-
defined. The purpose of the proposed study is to carefully enumerate the costs of a pediatric 
cancer treatment program in a low-resource setting.  Identification of these costs will help 
inform policy makers and funders about the affordability of cancer treatment in developing 
countries and will provide information needed to advocate for greater investment in fighting 
this growing burden. 
RESEARCH QUESTION 
The lack of data on the costs of delivering cancer treatment in low income countries 
has become a barrier to the further development of such systems by both national 
governments and external funders.  This study will answer the question, “What is the 
financial cost of treating a child with cancer in Rwanda?”   
Aim #1:  What is the cost of the cancer program in Butaro? 
Aim #2:  What is the financial cost of treating a child with Wilms’ Tumor? 
Aim #3:  What is the financial cost of treating a child with Hodgkin Lymphoma? 
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CHAPTER TWO:  LITERATURE REVIEW 
The literature review focused on the question:  what is known about the institutional 
costs of pediatric cancer treatment worldwide?  This systematic review investigated 
economic analyses of pediatric cancer programs and pediatric cancer treatments in 
countries of all income levels.  While our specific interest is in the provision of cancer 
treatment in low income countries, given the dearth of economic analysis in these countries, 
the review was not limited by setting.   
METHODS 
Variables and Inclusion/Exclusion Criteria 
Cost Perspective:  In investigating the cost of the delivery of care, the literature 
review will focus on articles related to costs of treatment at the health care provider, 
implementing agency and/or institutional level.  This review will be focused on assessing 
knowledge specific to delivering cancer care treatment and will therefore not include studies 
focusing solely on the cost of cancer to the individual or their family.  It will also not include 
studies specific only to the costs to society as a whole, in terms of lost productivity and/or 
mortality.  The review will focus on the costs of providing cancer treatment holistically and 
therefore, will not include studies that compare only one small portion of treatment (for 
example the cost of providing one anti-nausea medicine vs. another option) as these 
analyses often assume all other costs are equal and focus solely on the cost of the product 
or intervention in question.   
Childhood Cancer:  The review will include all childhood cancer types, including but 
not limited to Acute Lymphoblastic Leukemia (ALL), Hodgkin Lymphoma, Wilms tumor, and 
Burkitt lymphoma.  These common childhood cancers will be included in the search terms to 
ensure that the search captures all relevant articles.   
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Search Strategy 
The purpose of the literature review is to synthesize what is known about the cost of 
providing pediatric cancer care.  Therefore, the search strategy was intended to be broad 
and inclusive in order to gather as much of the published literature in this area as possible.  
Searches were conducted on PubMed and Web of Science. All articles meeting the above 
inclusion and exclusion criteria and published between 1995 and 2014 were considered for 
review.  All articles must have been published in English to be considered.  
Table 1 outlines the key concepts included in the search strategy.  Concepts 
represented by columns indicate searches conducted using OR.  Concepts identified by rows 
reflect AND strategies. 
Table 1: Literature Review Key Concepts 
Key 
Concepts 
Search Terms (each column reflects an OR in the search and each 
row reflects an AND) 
Childhood 
cancer 
“childhood 
cancer” 
“Pediatric 
oncology” 
ALL, Hodgkin’s, Wilms, 
nephroblastoma 
and/or Burkitt 
“neoplasms” 
Cost “cost” “cost analysis”  “economic” 
 
“economic 
analysis” 
Cancer 
Treatment 
treatment “cancer drugs” Chemotherapy Surgery or 
Radiation 
Analysis Strategy 
While the search strategy was intended to provide a broad representation of the 
available literature, the analysis strategy was utilized to ensure only those articles that met 
the inclusion/exclusion criteria were included.  Due to the relative lack of information and 
the need to synthesize current understandings, no data hierarchy was employed.  Titles and 
abstracts for the articles generated using the search terms were reviewed to determine 
those studies that met the inclusion/exclusion criteria.  Those studies that met the criteria 
were then fully reviewed.  The studies determined to be highly relevant were reviewed for 
pertinent citations, and the abstracts for those citations deemed to be appropriate to the 
research question were then reviewed and considered for inclusion. 
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The quality of the articles identified both through the online search strategy and the 
snowballing technique was assured by including only those articles that either appeared in 
peer-reviewed journal articles or those that were published from credible local or 
international sources, such as local government and/or multi-lateral reports. 
RESULTS  
The search methodology resulted in a total of 148 articles identified in PubMed and 
Web of Science as potentially relevant.  Of the original 148 articles, I eliminated a 
substantial number (138) for failing to meet the inclusion criteria after title and/or abstract 
review.  I identified an additional 3 studies through snowballing, or reviewing relevant 
articles to identify journal articles that had been missed in the key word searches.  After full 
article review, 13 articles met the inclusion criteria of the review.  I recorded all study 
characteristics, outcomes and notes in a summary spreadsheet. 
SUMMARY  
Results from the literature review represented 4 overarching categories of analysis 
related to the cost of pediatric cancer care:  literature reviews and overview narratives on 
the state of the research, studies investigating the financial cost of providing care, studies 
comparing costs for different treatment protocols for the same disease, and cost-
effectiveness studies.  The vast majority of findings related to costing the treatment of 
Acute Lymphoblastic Leukemia (ALL); one study examined Non Hodgkin Lymphoma (NHL), 
one examined Hodgkin Lymphoma and one study examined Burkitt Lymphoma.  All studies 
with one exception were conducted in either high or upper middle income economies as 
classified by the World Bank.   Only one study represented cost analysis of cancer treatment 
in a low income country. 
Literature Reviews And Overviews:  Four of the identified studies conducted 
systematic literature reviews or provided overviews on the state of our understanding of the 
economic dimensions involved in childhood cancer treatment.  Overall there was widespread 
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agreement that there is a need for more research on the costs of pediatric cancer 
treatment. 
In Beyond the Bench and the Bedside: Economic and Health Systems Dimensions 
of Global Childhood Cancer Outcomes, Denberg et al. advocate for greater analysis of the 
economic and health system dimensions of childhood cancer outcomes.  The authors 
highlight the relationship between national income and health investments and childhood 
cancer survival rates emphasizing that “estimated 5-year survival rates for children with 
cancer are directly proportional to a range of economic and health system indicators, 
including gross national income per capita, the number of physicians per 1,000 population 
and, most significantly, the annual government expenditure on healthcare per capita”.   
The authors note that “cost-effectiveness ratios for the treatment of pediatric cancer are 
highly favorable in HICs” and posit that resource-adapted protocols hold much promise 
for being cost-effective in low and middle income countries as well. 22 
 In “Economic evaluation of treatments for cancer in childhood” Barr, Feeny and 
Furlong advocate for institutionalization of economic evaluation within clinical trials in 
pediatric oncology.  The authors offer a framework for economic evaluations based on 
clinical eﬀectiveness, utility assessment and quality- adjusted life years and analysis of 
societal costs and propose that researchers who design clinical trials for childhood cancer 
should be challenged to justify decisions not to include such measures 23.  
 In a systematic literature review of economic evaluations of Non-Hodgkin’s 
Lymphoma (NHL) using Pub Med and Cochrane databases in English and Dutch, the authors 
analyzed the available economic evaluations for their descriptive abilities.  The authors 
developed a framework for judging each study based on 6 methodological indicators they 
deemed as high priority for the descriptive value of the study:  
1. Acknowledgement of the study perspective 
2. Inclusion of overhead costs 
3. Clearly stated sources of cost data  
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4. Valuation: costs based on resource consumption, not prices  
5. Clear data analysis strategy including sensitivity analysis 
6. Presentations of resource use and unit costs 
 The authors concluded that many therapies for NHL had yet to be economically 
evaluated.  Those studies that were evaluated were often found either to include 
methodological flaws (related to the 6 key indicators) or to be incomplete in the description 
of their methodology so that compliance could not be evaluated conclusively. 24 
Similarly, a literature review specific to health-related quality of life (HRQL) and 
economic outcomes of children with acute lymphoblastic leukemia (ALL) found few cost-
effectiveness studies and no published comprehensive economic evaluations.  The authors 
found a significant body of published literature with regard to HRQL measures in children 
with cancer but little related to the economic costs of treatment:   most costing studies the 
authors identified focused narrowly on a particular component of treatment. 25 
Financial Analyses:  Three studies investigated the financial cost of treatment in 
different contexts. 
A retrospective analysis of tumor registry data for 138 patients in South Africa using 
costs determined by 2008 tariff levels determined that the total cost of diagnosing, staging 
and treating  a child with Hodgkin Lymphoma and following up for 2 years post-therapy was 
ZAR $53,178.20 (or US $6,647.27) 26.   The analysis was limited in that it relied on prices 
not resource utilization and excluded salaries, consumables and hospitalization charges – 
elements that are known to be major cost drivers of treatment.   
A cost analysis of 11 patients diagnosed between 1991 and 1994 with ALL at Kuopio 
University Hospital in Finland found the total mean cost of treatment was US $103,250 
(ranging from US $55,196– $166,039) per patient 27.  Daily basic hospital costs based on 
time on the ward were added to patient-specific costs as determined through the hospital 
internal billing database.  Rahalia et al. determined that 53% of the total patient costs were 
basic hospital costs and 47% patient- specific costs.  The small number of patients, the 
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reliance on hospital charges and the wide variability in treatment for ALL limits the utility of 
the results. 
A similar analysis of treatment costs for pediatric ALL patients was conducted in 
China with 45 patients diagnosed between May 2005 and June 2006.  Liu et al. found that 
the overall average cost of treatment per patient was US $11,022.07 with clinic costs 
accounting for approximately US $3,700 and hospital cost accounting for about US $7,300 
28.  Both studies of ALL patients noted the wide variability in individual treatment patterns 
and the resultant effect on cost.  As these studies demonstrate even within the same 
disease, there are wide variations in cost, between both countries and individuals.     
Treatment Cost Comparisons:  Four of the articles represented cost comparisons 
between different treatment regimens.  Tong et al. investigated the cost difference between 
several different protocols for patients treated for childhood ALL in the Netherlands.  The 
authors analyzed patient-level data for 84 patients enrolled in 2 pediatric oncology centers 
in the Netherlands between April 2005 and October 2009.  Costs were found to be 
comparable between the first protocol (treatment with PEGasparaginase as first line drug 
followed by Erwinia asparaginase in case of allergy) and the second protocol (treatment with 
native E.coli asparaginase, followed by a switch to PEGasparaginase, and subsequently to 
Erwinia asparaginase in case of allergy).  The authors concluded that the first protocol was 
preferable given that it is administered less frequently “resulting in a reduced burden for the 
patient and family” 29.  However, the study was limited in that it did not investigate 
differences in outcomes between the 2 protocols or costs borne by the patient and their 
family. 
A second study investigated the difference in toxicity, supportive care and costs for 
two different Chemotherapy Protocols used in Russia to treat Childhood ALL. Von 
Stackelberg et al. conducted a single-center study to compare costs between a new Russian 
protocol (Moscow-Berlin 91) to a modified version of the protocol ALL BFM 90 in order to 
evaluate possible advantages of the new protocol under Russian conditions.  Costs were 
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calculated using prices in the German Rote Liste.  Findings were limited in that the analysis 
utilized prices charged to patients instead of the cost of resource utilization; however, 
because the main outcome was a comparison, the authors concluded that the comparison 
was more important than determining the absolute value.  The assessment was also limited 
in that it did not include the costs of disposable materials, solutions and outpatient 
treatment and travel.  Total costs of treatment and supportive care were found to be 1.73 
times higher for the existing BFM 90 protocol, while costs of cytostatic drugs and toxicity 
during therapy were comparable 30.  The authors concluded that the new MB91 protocol 
“appears to be an alternative to established protocols for countries with limited financial and 
clinical resources.” 
The third study, Economic Evaluation of Treatment for Acute Lymphoblastic 
Leukaemia in Childhood, investigated the difference in cost and health-related quality of life 
between 2 different widely-used treatment strategies: the Berlin-Frankfurt-Munster (BFM) 
and Dana-Farber Cancer Institute (DFCI) consortia’s treatment strategies.  In order to 
assess Heath-Related Quality of Life, “parents of children treated at seven centres in 
Canada, Italy and the USA completed health-related quality of life (HRQL) assessments 
during four active treatment phases and at 2 years after treatment” 31.  Costing data was 
provided by only one center.  Hospital service utilization and costs were assessed only for 
patients in the Province of Ontario using resource intensity weights (RIW) collected from the 
Discharge Abstract Database of the Canadian Institute for Health Information and costs 
obtained from the Ontario Case Costing Initiative.  Total treatment costs were found to be 
between US$40,559 to US$255,987 for the BFM treatment strategy and between 
US$43,242 to US$262,541 for the DFCI strategy.  The authors concluded that there was no 
significant difference in the mean total treatment costs or in health effects between 
protocols.   
Luo et al. compared the costs and event-free survival rates for 243 patients 
participating in one of three protocols in China.  Costs were assessed using patient fees for 
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“hospital beds; medications; therapy and procedures including nursing, lumbar puncture, 
intrathecal injection, bone marrow aspiration and parenteral injection; blood products; and 
others such as consultation, ultrasonography, electrocardiogram, radiological imaging, and 
pathology tests” 32.  Event-Free Survival was determined from the initiation of treatment 
through the date of last follow-up or the first treatment failure (including abandonment, 
death or relapse).  The study was undertaken to determine whether the development of the 
Economic Protocol (a less intensive regimen designed for patients who can’t afford the 
standard regimens) would produce lower costs and acceptable event-free survival rates.  
The cost of the Economic Protocol was shown to be the least expensive of the three 
regimens “with less intense chemotherapy, lower incidence of treatment-related 
complications and shorter duration of total hospital days”.  The authors found that the 
Economic Regimen produced EFS rates that were about 10% lower than the other 2 
protocols but also noted that a significant proportion of failure was due to abandonment due 
to inability to pay.  The authors proposed that funding to support treatment for those who 
cannot afford even the Economic Protocol would likely result in higher event-free survival 
rates. 
Cost-Effectiveness: Two economic analyses were identified that calculated the cost-
effectiveness of pediatric cancer treatment.  A Dutch study examined 50 children diagnosed 
with ALL from a single institution and determined costs per life year saved to be between US 
$1,962 and $2,655 33.  The cost-effectiveness ratio was found to be well within acceptable 
ranges for cost-effectiveness.  Costs were determined using in-house estimates for direct 
costs.  Outcomes were assessed using the national 5-year event-free survival rates.   
Bhakta et al. utilized the WHO-CHOICE (‘CHOosing Interventions that are Cost-
Effective’) framework for generalized cost-effectiveness analysis to estimate cost 
effectiveness of treating either acute lymphocytic leukemia (ALL) in Brazil or Burkitt 
Lymphoma (BL) in Malawi.  This method “defines cost effectiveness as the ratio of the 
monetary expense required to avert 1 DALY to the annual gross domestic product (GDP) per 
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capita of a given country or region. A ratio of 3:1 is considered cost effective” 34.   Children 
in Brazil with ALL achieved a 63% event-free survival rate at a cost of US $16,700 per 
patient, while 48% of the children in Malawi were cured with the BL protocol and a cost of 
less than US $50 per child.  The results in Brazil represent only 6% of the threshold of being 
very cost effective.  The results in Malawi represent less than 1% of the calculated US 
$14,243 threshold for very cost effective BL treatment.  The authors highlight that it “is a 
common assumption that treating children with cancer in LMIC is not cost effective”35.  The 
results of this research stand in stark contrast to that assumption.  However, it is important 
to note that the authors’ calculations of cost-effectiveness of BL were based on a study 
quoting the cost of chemotherapy drugs for BL pediatric patients in Malawi as “inferior [to] 
50 US dollars” 12.  Therefore, these calculations are limited in that they do not include fixed 
costs or variable costs outside of chemotherapy and supportive care drugs, such as 
infrastructure, healthcare worker salaries, and/or radiology/laboratory equipment. These 
costs can be substantial but will vary greatly with the health system.  Many cancer 
programs are built to leverage existing infrastructure; however, these costs should be 
considered in future studies. 
DISCUSSION   
Methodologies for costing studies of pediatric cancer vary greatly depending on the 
various potential uses and purposes for conducting studies.  In addition, the lack of readily 
available financial information and/or standardized financial information across systems led 
many researchers to choose the less rigorous but more accessible path of basing the 
analysis on patient prices as opposed to resource consumption.  Where cost information was 
available, costs varied widely between diseases, patients and protocols. 
Most of the studies in the review analyzed the cost of providing treatment for ALL 
patients.  These studies found costs ranging from a low of approximately $11,000 per 
patient in middle income countries to a high of around $100,00 in high income countries.  In 
addition to the differences in costing methodologies between studies, the costs of labor, 
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services and chemotherapy drug prices vary widely between countries and likely account for 
the vast differences in the cost per patient seen in these studies.  One study examined 
treatment for Hodgkin Lymphoma in South Africa, an upper-middle income country as 
classified by the World Bank.  This study found the total cost of diagnosing, staging and 
treating a child with Hodgkin Lymphoma to be $6,647.27.   
The cost of providing treatment for childhood cancer in low income countries remains 
largely unknown.  Vast differences in labor costs, treatment regimens, and chemotherapy 
and drug costs between cancer programs in high and low income countries lead to difficulty 
in understanding how costs may transfer to low resource settings.  Only one article was 
found that captured the cost of providing care in a low income country:  the cost-
effectiveness study comparing the effectiveness of treating either acute lymphocytic 
leukemia (ALL) in Brazil or Burkitt Lymphoma (BL) in Malawi.  Forty-eight percent of the 
children in Malawi were cured with the BL protocol at a cost of less than US $50 per child.  
However, because the analysis in Malawi was built on the costs of chemotherapy 
medications alone and the original costing study did not include the costing methodology, 
comprehensive costing analyses are needed to understand the true costs of treating these 
diseases.   
The literature review was successful in identifying the extent of knowledge on the 
cost of delivering cancer care to children.  Nevertheless, the findings were limited by a 
publication bias.  Clearly there is more that is known by those practicing in the field than 
what is published in the literature, as evidenced by expert opinion, commentaries and 
reviews.  There are many factors that could contribute to lack of publications, particularly in 
low resource settings:  cancer programs tend to be relatively new, data is often non-
existent or poor quality, practitioners are overwhelmed and have little time to publish, and 
outcomes are often poor.  Economic analyses of cancer treatment have been increasing 
over the last several years and many studies are currently in progress.  The inclusion of 
published reviews that incorporated expert opinion allowed me to capture some of the 
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existing unpublished, practical knowledge.  Yet, in including only published studies, the 
literature review may be missing significant applied knowledge that would impact 
implementation.  Within the studies that were published, significant limitations were noted.  
The studies often involved small sample sizes with frequent broad estimates used for 
missing financial data.  In addition, many studies did not include costs such as labor or 
overhead in the analysis, impacting the potential utility of the findings.  While these 
limitations should be considered when assessing the practical application of this knowledge, 
they do provide enough consensus to point toward areas of necessary research. 
A full accounting of the costs across childhood cancer diagnoses should be 
considered in future studies, particularly to assist those who are considering building cancer 
programs.  The cost of beginning a cancer treatment program is often cited as a primary 
barrier to establishing these programs in low income countries; as a result, a complete 
accounting of the cost of delivering care could have significant policy ramifications and 
would help funders to better understand the dimensions of the investment necessary. 
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CHAPTER THREE:  THE RWANDAN CONTEXT 
HEALTH CARE IN RWANDA  
Rwanda is a largely rural country with a population of 11 million people, almost 5 
million of whom are under the age of 15.  The country ranks 167th on the Human 
Development Index.  Rwanda has a per capita income of $644 US and a poverty rate of 
44.9% with 24.1% of the population living in extreme poverty.36 The genocide in 1994 had 
a significant and lasting impact on the country and its healthcare infrastructure. Coming out 
of the genocide, Rwanda established Vision 2020, a government-led development program 
intended to “overcome poverty and foster unity and reconciliation.”37  Through the 
implementation of this vision, Rwanda has made significant strides in improving the health 
and welfare of its people. Life expectancy has increased dramatically from 28 years in 1994 
to 56 years in 2012.  Over 77% of the population lived below the poverty line in 1994: by 
2010, less than 45% were living in poverty.38  In addition, Rwanda is now on track to 
achieve the health-related Millennium Development Goals.  The current implementation 
plan’s overarching goal is to accelerate “progress to middle income status and better quality 
of life for all Rwandans” by increasing the average annual economic growth to 11.5% and 
accelerating the “reduction of poverty to less than 30% of the population”.37  Expanding 
access to quality healthcare will continue to be a key focus of the plan moving forward. 
Rwanda invests $55 per person on public health and health care expenses each year, 
ranking in the middle of spending for countries in Sub-Saharan Africa.39  Health care is 
delivered through a decentralized system consisting of 18 dispensaries, 34 health posts, 
over 430 health centers, 39 district hospitals and 4 national referral hospitals that offer 
specialized inpatient and outpatient care.40  Rwanda has been internationally recognized for 
their innovative approaches to improving access to high quality health care. The country 
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employs Results Based Financing (RBF), a financing mechanism that provides payment 
based on achievement of measurable outcomes, such as number of children immunized or 
number of institutional deliveries. This approach has led to increases in curative care visits 
per person from 22 to 55 percent and in the number of institutional deliveries from 12 to 23 
percent.41  This financing system is now being considered as a model for other countries. In 
addition, Rwanda established a new national insurance system in 2004.  The minimum 
package of benefits through Mutuelle de Sante covers comprehensive preventative services 
and primary care, as well as all services and drugs provided by the health centers.  
Members pay an annual fee of $6 USD per family member as well as a 10% service fee for 
each visit.  Enrollment is voluntary and fees are adapted by income.  The government 
covers the costs for the poorest 25% of the population.  Enrollment in the program was as 
high as 91% in 2010 but in recent years has dropped to 73%.40   
Cancer Care in Rwanda 
The Butaro Hospital in the northern Burera district is home to the Cancer Center of 
Excellence at Butaro Hospital, the referral center for cancer care for both the district and the 
country.  Opened in January 2011, the Butaro Hospital was established as part of the effort 
to rebuild the Burera district’s health system. This 160-bed district hospital provides four 
basic services:  maternity, internal medicine, surgery and pediatrics as well as an 
emergency department, outpatient ophthalmology and gynecology services, an ear nose 
and throat clinic and extensive laboratory capabilities.  The creation of the hospital was the 
result of a collaboration between Partners In Health (PIH) and the government of Rwanda.  
Partners in Health is a US-based non-profit co-founded by Paul Farmer and committed to 
bringing the benefits of modern medical science to those most in need.  The NGO began 
work to strengthen the public health system in the country at the request of the 
government in 2005.   Along with the organization’s Rwandan sister organization, Inshuti 
Mu Buzima (Kinyarwanda for “Partners In Health”), PIH created a primary health care model 
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using HIV/AIDS care as an entry point for addressing the major health problems of the rural 
poor.   
In the beginning of the partnership, cancer was not a priority for either the 
government or the local health care providers.  However, successful treatment of a young 
pediatric cancer patient encouraged other people to seek treatment and practitioners soon 
saw a steady flow of patients with cancer seeking treatment.42  The Cancer Center of 
Excellence at Butaro Hospital was built to respond to this growing burden. Inaugurated in 
July of 2012, this 24 bed facility offers preventive care, pathology-based diagnosis, 
chemotherapy, referral for radiotherapy, follow-up, and palliative care, as well as 
psychosocial and practical support such as mental health and social work services, food, 
transportation, and home visits. Imaging and surgery are provided at the national referral 
hospital in the capital, 3 hours away.  All cancer care is provided free of charge regardless 
of the patient’s ability to pay.   Between July 2013 and June 2014, 2,576 new oncology 
patients were seen at the Butaro Hospital Center with 1,290 representing newly enrolled 
patients.   
There are currently approximately .05 doctors per 1,000 residents in Rwanda.43  In 
2010, there was one oncologist for the entire population of 11 million people and no 
pediatric oncologists.43 Compare this to the United States, where there are approximately 
3.8 oncologists per 100,000 people.44  As a result, care at the Butaro Cancer Center is 
provided by general practitioners with special training in oncology as well as Butaro-based 
internist and pediatric specialists.  Partners in Health partners with Dana-Farber Cancer 
Institute (DFCI) to provide care and mentorship to providers at PIH sites in Rwanda.  Local 
nurses provide chemotherapy and are mentored by visiting specialty nurses from DFCI. The 
Rwandan providers are supported by US-based oncologists with weekly structured phone 
calls and additional communication as necessary.  
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Childhood Cancer in Rwanda 
An analysis of cancer registries between 2007 and 2011 revealed 320 pediatric cases 
registered in Rwanda overall.  (Rudakemwa et al., 2012) The Partners in Health Butaro 
Cancer Center - which provides the only source of free cancer care in the country - recorded 
only 102 cases of childhood cancer diagnosed between July 2012 and June 2013.43  Based 
on population levels, approximately 700 pediatric cancer cases are expected to be 
diagnosed each year.45  This discrepancy could point to a significant level of cancer 
remaining undiagnosed in this population.   
This study will determine the cost of treating childhood cancer in Rwanda at the 
Cancer Center of Excellence at Butaro Hospital.  The analysis will determine the annual cost 
for the cancer center overall and then focus specifically on the per patient costs for treating 
2 childhood cancers:  Nephroblastoma (or Wilms’ Tumor) and Hodgkin Lymphoma, which 
were identified in the literature review as two of the most common diagnoses.   
Nephroblastoma, or Wilms’ Tumor, is a common kidney cancer affecting children. 
Between July 2012 and June 2014, Wilms Tumor was the most common childhood 
malignancy seen at the Butaro Cancer Center, representing more than 20% of pediatric 
cancer diagnoses.46  35 cases of nephroblastoma were diagnosed at Butaro Hospital 
between July of 2013 and June of 2014.  The majority of cases occur in children below the 
age of 5.  Patients will often present as a malnourished child with a swollen abdomen and 
no acute pain or severe malaise.  Diagnosis is primarily accomplished with ultrasound.  In 
addition, chest x-rays can be conducted to detect metastases in the lungs.  The treatment 
protocol for Wilms’ Tumor in Rwanda consists of 4-6 weeks of chemotherapy, surgery, and 
then 5 cycles of post-operative chemotherapy delivered in 3 week intervals.   
A recent study examining 54 patients evaluated or treated for nephroblastoma at the 
BCCOE between July 1, 2012 and June 30, 2014 reported a survival rate of 57.4%.   Thirty-
one patients remained alive at the end of the study period with all but one disease free, 
29.6% (16) died and 13.0% (7) were lost to follow up; 5 during treatment and 2 post-
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treatment.  While the results of the study are preliminary and more follow-up will be 
required, the initial relapse and loss to follow up rates are lower than those seen in other 
low and middle income country studies.  These outcomes present a strong argument that 
effective cancer treatment is possible in low income countries.  
Hodgkin lymphoma is a cancer of the lymphatic system affecting both children and 
adults.  The disease is most often diagnosed in people between the ages of 15 and 35 as 
well as those older than 55 in developed countries; although, Hodgkin lymphoma has a 
higher incidence in children under the age of 15 in developing countries.47 Survival rates in 
developed countries are over 90%, while those in African countries are significantly lower, 
ranging from 64% to 71.4%.48 Patients in Rwanda often present with enlarged painless 
lymph nodes, a mass in the chest with difficulty breathing, and/or an abdominal mass with 
abdominal symptoms.  Patients may also experience fever, night sweats or significant 
weight loss.  Diagnosis is accomplished through a biopsy and diagnostic and radiological 
tests.  The Rwandan treatment regimen includes chemotherapy administered every 28 days 
for 6 cycles.  Anti-emetics are considered an essential component of supportive care. Seven 
pediatric cases of Hodgkin Lymphoma (and approximately 23 adult cases) were diagnosed 
between July of 2013 and June of 2014 at Butaro Cancer Center.  Outcome data is not yet 
available for Hodgkin Lymphoma patients.  Initial outcomes are currently under review. 
22 
CHAPTER FOUR:  STUDY DESIGN AND METHODOLOGY 
METHODOLOGY AIM #1:  COST OF THE ONCOLOGY PROGRAM IN BUTARO 
Our first study aim was to determine the overall cost of the cancer program at the 
Butaro Cancer Center of Excellence, including both pediatric and adult diagnoses.  We 
conducted a retrospective costing analysis from the Ministry of Health point of view utilizing 
secondary data from the administrative systems of the Cancer Center of Excellence at 
Butaro Hospital.  Costs were assessed during the 2014 fiscal year - between July 1, 2013 
and June 30, 2014.  Each of the following sources provided data for the study: 
1. Butaro Hospital Balance Sheet for the last complete fiscal year (July 2013-2014) 
2. PIH Rwanda NCD FY14 Program Balance Sheet (July 2013-June 2014) 
3. PIH Burera District Budget 
4. PIH Procurement/Pharmacy Invoices 
5. Program Data on patients diagnosed and treated between July 2013 and June 
2014 in each category of disease 
6. 2012 Rwandan National Reference for Rates and Hospital Centres 
All costs paid in Rwandan Francs were converted to US Dollars using the January 
2014 exchange rate of 680.45RWF to 1 USD. 
The methodology distinguishes between 2 different cost categories:  
 Fixed Costs:  Fixed costs are those costs that remain constant despite the number 
of patients treated.  Examples of fixed costs within the Butaro Hospital budget 
include electricity and utilities, repairs and maintenance, program costs and 
expenses.  Start-up costs were separated from annualized overhead costs to allow 
for easier program planning and future cost predictions. 
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 Variable Costs:  Variable costs change with patient volume and will include 
chemotherapy drug costs, supportive medication costs, labor costs, laboratory 
tests and social support.   
Table 2 summaries the oncology program cost categories and the significance of each 
category. 
Table 2: Oncology Program Cost Categories and Significance 
Cost 
Category 
Description Line Items Included Significance 
Fixed Costs costs necessary to 
run the program on a 
regular basis that 
remain constant 
despite the number 
of patients treated 
o Overhead (building 
repairs and 
maintenance, 
electricity and utilities) 
o training 
o vehicle purchases 
o equipment purchases 
 
The annual operating 
costs help to inform 
the minimum annual 
financial burden to 
effectively support the 
program. 
Variable 
Costs 
recurrent costs 
necessary to run the 
program on a regular 
basis that change 
with patient volume 
o chemotherapy drug 
costs 
o supportive medication 
costs 
o salaries 
o pathology costs 
o Social support:  
patient transport fees, 
food supply, and other 
social support  
The annual variable 
costs help clarify the 
ongoing cost per 
patient served. 
The costing model detailed below outlines a description of each cost category and the 
methodology for each cost category. 
Fixed Costs    
Start-Up Costs: All one-time, non-recurrent capital expenditures associated with the 
Butaro Cancer Center were identified including: original construction costs of the hospital 
space, renovation costs of the hospital to prepare the Cancer Center and equipment and 
supply purchases for pathology lab and ward.  For each cost, we included the actual price 
paid by the program which included items that were purchased at a significant discount.    
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Overhead: The Butaro Cancer Center budget and the Butaro Hospital Budget were 
reviewed and cost category line items were divided into fixed and variable costs.  The 
following fixed cost categories were identified for services shared with the hospital: 
 Fuel for Hospital Generator 
 Vehicle maintenance, fuel and repair  
 Sewage, Electricity and Plumbing 
 Equipment maintenance and repair  
 Electricity 
 Communications 
 Security 
 Landscaping 
 Taxes and bank fees 
 Cleaning and laundry 
 Cleaning Supplies 
No waste disposal costs were reported and are therefore not included. 
The following fixed cost categories were identified as directly attributable to the 
Cancer Program: 
 Office Supplies  
 Training 
 Communication cards for oncology staff 
For each shared service category, a percentage of the total was allocated to the 
cancer program on the basis of square footage, with the exception of “Equipment 
maintenance and repair” which was allocated based on the equipment specific to the cancer 
ward out of the total equipment for the hospital.  The totals for these categories were added 
to the costs directly attributable to the Cancer Program for a total Fixed Cost of the Cancer 
Program.  All costs associated with overhead were annualized. 
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Variable Costs 
 Chemotherapy Costs:  All chemotherapy medications for the Oncology Program are 
procured and paid for by Partners in Health. All purchases and emergency orders for 
chemotherapy medications and consumables related to the Oncology Program were totaled 
for the fiscal year 2013-2014.   
Supportive Medication Costs:  Supportive care is often necessary to mitigate the 
side-effects of cancer treatment such as anti-emetics and pain management drugs.  
Supportive medications are procured and paid for from multiple sources. All supportive care 
medications and consumables were identified and calculated through the PIH procurement 
department.  Non-chemotherapy related supportive medications and consumables (such as 
paracetamol) were calculated using the hospital pharmacy quarterly requisition sheet. We 
cross-referenced a list of the quarterly supportive meds and consumables (and quantities) 
ordered by the Butaro pharmacy for the last quarter with the annual price list from the 
pharmacy to develop an estimate for the total supportive meds and consumables ordered in 
the quarter which we then used to estimate costs over the full year and then allocated to 
the cancer program based on the proportion of beds. 
Radiotherapy:  Because there are no radiotherapy capabilities in-country, patients in 
need of radiotherapy are sent to Uganda.  All costs related to treatment in Uganda, 
including transport, medical bills and meals were totaled for the year. 
Lab Tests, Imaging and Surgery:  Services unavailable at the Butaro Cancer Center 
are conducted in the primary hospitals in Kigali.  Services provided to the oncology program 
from the University Central Hospital of Kigali (CHUK) and the Rwanda Military Hospital 
(RMH) include lab tests (such as BHG, PSA and TSH), CT scans, and surgeries.  Records 
were not available for 2014 costs; invoice totals from the 2015 calendar year were used to 
estimate the total cost to the program of these services. 
Blood Products:  All blood products are provided free of charge to local hospitals 
through the National Center for Blood Transfusion Division (NCBT).  The NCBT’s mission is 
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to provide safe, effective and adequate Blood and Blood products to all patients in need by 
promoting voluntary non - remunerated blood donation across the country.  Blood product 
orders placed in 2015 were used to determine a monthly average in order to estimate the 
total cost of blood products during the study period.   
Social Support Costs:  Social support is often necessary to ensure a patient’s ability 
to complete a full course of treatment.  Patients may need transportation, food and shelter 
costs covered in order to be able to access treatment. Costs directly attributed to the 
Oncology Program were identified within the District Budget and NCD Budget.  Relevant 
costs included assistance with burial costs, transportation to and from treatment, and new 
housing for cancer patients.  All relevant social support costs from both the District and the 
NCD budgets were totaled for the year. 
Labor Costs:  All paid staff supporting the Oncology Program were identified 
including:  cashiers, anesthetists, an archivist, a stock manager, plumbers, data managers, 
drivers, lab techs, electricians, doctors, nurses, social workers, and a nutritionist.  Each 
position’s annual salary was assessed, including allowances for transportation and 
accommodation.  Additional amounts for RAMA (Rwanda’s Medical Insurance Agency) and 
RSSB (Rwanda Social Security Board) were included.   
Provision of care is significantly bolstered by doctors who either volunteer their time 
to the cancer program or are paid by their host institution.  Because this labor is readily 
available free of charge to the cancer program from multiple sources, and we anticipate that 
the program will continue to have access to free labor regardless of the source, the cost for 
volunteer labor was not included in this analysis.  However, the inclusion of volunteer costs 
is modeled in the scenario analysis. 
Pathology:  Butaro Hospital includes an anatomic and clinical pathology laboratory 
that processes close to 2000 samples each year.  The development of the lab and training of 
the team is the result of a close collaboration by Partners In Health, Butaro Hospital and the 
Brigham and Women’s Cancer Center.  The partners work together to track patient samples 
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and provide technical and diagnostic consultations.  US-based volunteer laboratory 
technicians and pathologists also provide mentorship both in country and remotely.  In 
2014, a telepathology system was initiated allowing for increased diagnostic capacity, 
decreased turn-around time, and improved training.  A diagnosis of cancer is determined 
through the pathology lab where samples are prepared and processed.  During the time 
period of this study, no local pathologists were available for diagnosis.  As a result, samples 
were either shipped to Boston for review at the Brigham and Young Medical Center or 
uploaded for remote pathology review using a telepathology system.  Samples uploaded to 
the telepathology system were reviewed by one of 4 US-based volunteer pathologists.  Each 
volunteer pathologist worked no more than 4 hours per week.  During the time of the study, 
these services were donated free of charge to the program 
Costs to the program for the development of pathology services were captured in the 
NCD Budget and included items such as shipment of samples to Boston, training and travel 
costs for pathology lab technicians, and customs and duties for reagents.  Pathology 
services were provided by the Brigham and Women’s Hospital free of charge to the program 
and are therefore not included in the analysis.  Similar start-up support could be expected 
for future sites.  However, the program has now moved to a system utilizing local 
pathologists so future costs are predicted with the cost of local pathologists included. 
METHODOLOGY AIM #2:  COST OF TREATING A CHILD WITH WILMS’ TUMOR 
Overhead  
An annualized total for fixed start-up costs and equipment and supplies for the 
cancer center was calculated and a proportion was assigned based on the total number of 
oncology patients.  All annual overhead costs for the oncology program were assigned to 
each patient treated based on patient volume and time on the ward.   
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Chemotherapy and Supportive Care Medications:   
The treatment protocol outlined above require a number of both chemotherapy and 
supportive care drugs for each patient.  All chemotherapy and supportive care drugs were 
enumerated following the established protocol for treatment of each disease in Rwanda.  
Based on practitioner advice as to the average size of a typical patient, the costing assumes 
a .6m2 body surface area for the patient.  For each drug: the number of cycles, the dose per 
cycle and the total dose in mg per cycle was calculated according to the following equations: 
 # of vials required per cycle = (individual recommended dosage*body surface  
area)/# of mg in available vial size [answer is rounded up to the next whole 
number] 
 Price for a full course of treatment = # of vials required per cycle*# of  
 cycles*price/vial 
This methodology calculates drug usage as well as waste and leads to conservative 
estimates, as prices can be significantly reduced by either procuring smaller additional vial 
sizes and/or treating more patients with the same disease on the same days.   
CT Scans and Surgery   
CT Scans and Surgery are conducted off-site at the primary hospital in Kigali. The 
national health insurance, Mutelle de Sante, covers 90% of all costs with the program 
covering the additional 10% for vulnerable patients.  The 2012 Rwandan National Reference 
for Rates and Hospital Centres was used to determine the full cost of appropriate CT Scans 
and Surgery per patient.   
Radiotherapy 
Radiotherapy is used in limited situations where the intent is curative.  The average 
cost per patient of radiotherapy was adjusted to reflect the low volume of patients receiving 
this treatment. 
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Blood Products   
All blood products are provided free of charge to local hospitals through the National 
Center for Blood Transfusion Division (NCBT).  The cost given by the NCBT for each RBC 
unit is $88.  Provider interviews were used to determine an average use of 5 RBC units (Red 
Blood Cell units available for transfusion) per patient over the treatment cycle.   
Transportation Costs   
The Butaro Cancer Center is located in a remote district of Rwanda, 3 hours from the 
capital.  Transportation support is a critical component of the program.  The median round 
trip cost of transport was combined with the average number of trips for a full course of 
treatment and follow-up to determine the full cost per patient of supporting transportation 
for treatment.   
Labor Costs   
We identified all relevant hospital staff involved in the treatment of pediatric cancer 
patients including doctors, nurses, social workers, cashiers, intake coordinators and 
pharmacy staff. We then interviewed clinicians to determine the major activities performed 
in treating each type of cancer and created process maps to estimate the amount of time 
each type of provider spends on each activity with each patient.  We adjusted staff salaries 
by the estimated total number of paid hours worked each year to determine a cost per hour 
for each provider.  The cost per hour was allocated by provider to the relevant patient care 
activities in order to create a total staff cost per patient.  
METHODOLOGY AIM #3:  COST OF TREATING A CHILD WITH HODGKINS LYMPHOMA 
Overhead   
An annualized total for fixed start-up costs and equipment and supplies for the 
cancer center was calculated and a proportion was assigned based on the total number of 
oncology patients.  All annual overhead costs for the oncology program were assigned to 
each patient treated based on patient volume and time on the ward.   
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Chemotherapy and Supportive Care Medications   
The treatment protocol outlined above require a number of both chemotherapy and 
supportive care drugs for each patient.  All chemotherapy and supportive care drugs were 
enumerated following the established protocol for treatment in Rwanda. Based on 
practitioner advice as to the average size of a typical patient, the costing assumes a 1m2 
body surface area and weight of 30kg for the patient.  For each drug: the number of cycles, 
the dose per cycle and the total dose in mg per cycle was calculated according to the 
following equations: 
 # of vials required per cycle = (individual recommended dosage*body surface 
area)/# of mg in available vial size [answer is rounded up to the next whole 
number] 
 Price for a full course of treatment = # of vials required per cycle*# of 
cycles*price/vial 
This methodology calculates drug usage as well as waste and leads to conservative 
estimates, as prices can be significantly reduced by either procuring additional vial sizes 
and/or treating more patients with the same disease on the same days.   
CT Scans and Radiotherapy  
CT Scans are currently not part of the protocol for the treatment of pediatric Hodgkin 
Lymphoma.  While 5 HL patients (or 17% of the total) received one CT Scan during the 
study period, this was often the result of a consultation outside the Butaro Cancer Center 
and is not part of the established protocol.   Therefore, the cost of CT Scans was not 
included in the analysis. If residual disease exists after chemotherapy, in rare cases a 
patient can be sent to Uganda for radiotherapy.  Given the rarity of this occurrence, this 
cost was not included in our analysis. 
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Blood Products  
All blood products are provided free of charge to local hospitals through the National 
Center for Blood Transfusion Division (NCBT).  The cost given by the NCBT for each RBC 
unit is $88.  Provider interviews were used to determine an average use of 7 RBC units (Red 
Blood Cell units available for transfusion) per patient over the treatment cycle.   
Transportation Costs   
The Butaro Cancer Center is located in a remote district of Rwanda, 3 hours from the 
capital.  As a result, transportation support is a critical component of the program.  The 
median round trip cost of transport was used along with the average number of trips for a 
full course of treatment and follow-up to determine the full cost per patient of supporting 
transportation for treatment.   
Labor Costs   
We identified all relevant hospital staff involved in the treatment of pediatric cancer 
patients including doctors, nurses, social workers, cashiers, intake coordinators and 
pharmacy staff. We then interviewed clinicians to determine the major activities performed 
in treating each type of cancer and created process maps to estimate the amount of time 
each type of provider spends on each activity with each patient.  We adjusted staff salaries 
by the estimated total number of paid hours worked each year to determine a cost per hour 
for each provider.  The cost per hour was allocated by provider to the relevant patient care 
activities in order to create a total staff cost per patient.  
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CHAPTER FIVE:  RESULTS 
AIM #1: BUTARO CANCER CENTER OF EXCELLENCE 
We conducted a retrospective costing analysis utilizing secondary data from the 
administrative systems of the Cancer Center of Excellence at Butaro Hospital.  Costs were 
assessed between July 1, 2013 and June 30, 2014 from the Ministry of Health perspective.  
We determined the annual operating cost of the cancer program at the Butaro Cancer 
Center of Excellence to be $953,499.  An additional $556,105 was assessed as start-up 
funds necessary to run the program within the existing infrastructure. 
Fixed Costs 
Start-Up Costs:  All start-up costs for the program totaled $556,105 (Table 3).  This 
included the cost of constructing and renovating the hospital to build the Cancer Center and 
an ambulance purchase as well as the equipment and supply purchases necessary to equip 
the pathology lab and ward.  Equipment for the pathology lab included all equipment 
necessary to run the lab, such as microtomes, tissue processors and cameras and 
microscopes.  Training costs included those related to the national Baseline Cancer Care 
Training.  This initiative, supported by GlaxoSmithKline, trained nurses and doctors across 
the country to gain foundational knowledge on cancer, its epidemiology, and available 
treatments, as well as the main cancers and treatment priorities in Rwanda.  As a train- 
the-trainer initiative, limited training costs are on-going; however, the bulk of the program 
cost was a one-time expense intended to foster a robust referral network and early 
diagnosis system for the country. 
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Table 3: Oncology Program Start-Up Costs 
Cost Component  Total Cost  
Construction of Hospital  $327,815  
Cancer Center Renovation  $25,461  
Pathology Lab  $100,848  
Staff Housing  $10,910  
National Baseline Training  $74,100  
Ambulance Purchase  $16,970.45  
Subtotal Start-Up Costs  $556,105  
Overhead: Table 4 outlines the cost categories pertaining to overhead expenses 
during the 2013-2014 fiscal year.   Services shared with the hospital were allocated to the 
cancer program on the basis of square footage.  Administrative salaries for the hospital 
were estimated to be $250,796 and were then allocated to the cancer center on the basis of 
beds. Expenditures directly attributable to the cancer program were totaled.   
Table 4: Oncology Program Overhead Expenses 
Expenditure Category Total Cost in USD 
Vehicle maintenance, fuel and repair   $4,861.17  
Sewage, Electricity and Plumbing  $7,994.99  
Equipment maintenance and repair   $1,713.62  
Communications  $88.17  
Security, Landscaping and Cleaning 
Supplies 
 $4,352.27  
Office Supplies  $1,881.40  
Taxes and Fees  $3,023.23  
Administrative Salaries $41,799.27 
Training:  Training costs across all relevant trainings totaled $60,434 including 
trainings related to palliative care, pathology, basic cancer training, and cervical cancer 
training. All trainings that were necessary to support the Cancer Program were included at 
their full cost, even if other departments benefitted – for example, the Palliative Care 
Training applied to all NCD staff but was critical for the cancer team. 
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Variable Costs 
 All purchases and emergency orders for chemotherapy medications, supportive care 
and consumables related to the Oncology Program for the fiscal year 2013-2014 totaled 
$134,920 US.  This included purchases of anti-cancer drugs, supportive drugs such as anti-
nausea medications, and consumables.  
 A total of $236,844 was incurred for patients receiving radiotherapy in Uganda, 
including transport, medical bills and meals. 
The cost of the delivery of pathology services was found to be $58,190, including 
items such as shipment of samples to Boston, training and travel costs for pathology lab 
technicians, customs and duties for reagents, and consumables related to the pathology lab.  
Pathology services for samples sent to Boston were provided by the Brigham and Women’s 
Hospital free of charge to the program.  Samples that were not sent to Boston, were 
uploaded to the telepathology system and reviewed by one of 4 US-based volunteer 
pathologists.  Each volunteer pathologist worked no more than 4 hours per week.  These 
services were also donated free of charge to the program.  Because all start-up pathology 
services were available free of charge to the program and would likely continue to be if new 
sites were constructed, the cost of providing these services is not included in the cost 
analysis.  However, all costs that the program does incur (such as shipping and customs) 
were included. A model for estimating the cost of providing these services in-house is 
included in the Forecasting Future Costs analysis. 
The total cost of services provided to the oncology program from the University 
Central Hospital of Kigali (CHUK) and the Rwanda Military Hospital (RMH) was estimated to 
be $75,125, including lab tests, CT Scans, and surgeries. 
Social services were viewed as an essential component of treatment:  without this 
support, a patient’s ability to complete a full course of treatment may be severely limited. 
Social support expenditures at the District level and from PIH totaled $21,117. Relevant 
costs included assistance with burial costs, transportation to and from treatment, and new 
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housing for cancer patients. The majority of the cost ($15,824) was directly related to 
providing patient housing. 
Annual salaries for all paid staff supporting the Oncology Program totaled $196,755.  
Table 5 outlines positions, salaries and percent time attributed to the cancer program.  
Salaries included allowances for transportation and accommodation as well as RAMA 
(Rwanda’s Medical Insurance Agency) and RSSB (Rwanda Social Security Board) and were 
adjusted in accordance with time dedicated to the cancer program.  Positions shared across 
all hospital functions were allocated on the basis of the proportion of beds dedicated to the 
cancer program.   
Table 5: Oncology Program Labor Costs 
Role # of 
Staff 
% Time Attributed 
to the Cancer 
Program 
Total Annual Salary 
attributed to the 
Cancer Program in 
USD 
Anesthetist 3 30%  $6,284  
Archivist 1 100%  $2,933  
Cashier 3 17%  $1,496  
Billing Officer 4 17%  $1,994  
Data Officer 2 100%  $6,909  
Driver 5 17%  $793  
Electrician 2 17%  $1,108  
Histopathology Lab Tech 3 100%  $20,572  
Lab Tech 4 20%  $3,657  
Physician 2 100%  $27,692  
Nurse 18 100%  $99,588  
Plumber 2 17%  $882  
Social Worker 1 100%  $3,585  
Stock Manager 1 17%  $1,213  
Cooking Cooperative 1 17%  $5,044  
Cleaning Cooperative 1 17%  $11,766  
Nutritionist 1 25%  $1,237.72  
TOTAL in USD      $196,755  
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Total Costs 
The total annual operating cost for the Butaro Cancer Center of Excellence was 
estimated to be $953,499 (Table 6).  This represents the cost of treating 1,290 new 
patients and an additional 1,286 existing patients during the study period.  The cost of 
chemotherapy, radiotherapy, and labor were the most significant cost drivers for the 
program.  Surprisingly, given the relatively low number of patients sent to Uganda, 
radiotherapy services were the most significant cost driver comprising 25% of program 
costs.    Labor was the second largest cost driver, accounting for 21% of the overall cost, 
followed by chemotherapy and supportive medications and consumables at 15%. Overhead, 
training, CT scans and surgeries, blood products, non-chemotherapy related medications 
and supplies, pathology, and social services all accounted for less than 10% of the total.  
Figure 1 presents the proportions of cost by category. 
Table 6: Total Cost for the Butaro Cancer Center across All Categories 
COST CATEGORY  TOTAL COST IN USD  
Overhead   $65,714  
Training  $60,434  
Chemo and Supportive Med Procurement  $139,134  
Non-Chemotherapy Related Medications and Consumables  $40,456  
Pathology   $58,190  
Blood Products  $59,730  
Radiotherapy  $236,844  
CT Scans and Surgeries  $75,125  
Social Services  $21,117  
Labor  $196,755  
TOTAL PROGRAM COST for FISCAL YEAR 2013-2014  $953,499  
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Figure 1: Proportion of Cost by Cost Category 
AIM #2: WILMS TUMOR 
We determined the cost of a full course of treatment for a child with Wilms Tumor at 
the Butaro Cancer Center of Excellence to be $2,036 (including diagnosis, treatment and 
follow-up).   
Chemotherapy   
Assuming a child with a BSA of .6m2, a weight of 15kg and metastatic Wilms Tumor, 
the Rwandan protocol calls for 9 doses over 9 weeks of vincristine (1.5 mg/m2, maximum 
2mg), 5 doses (every other week) of actinomycin D (45 ug/kg IV, maximum 2mg) and 3 
doses Doxorubicin 50mg/m2 before surgery.  This is followed by 11-weeks of vincristine (1.5 
mg/m2, maximum 2mg), 5 doses of actinomycin D (45 ug/kg IV, maximum 2mg) and 5 
doses Doxorubicin 50mg/m2 post-surgery.  Costs per patient are outlined in Table 7. 
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Table 7: Chemotherapy Costs for Wilms Tumor Patients 
Drug Unit Price  
(in $US) 
# vials needed for 
full cycle 
Total Price  
(in $US) 
Vincristine 1.1 20  $22.00  
Actinomycin-D 12.5 20  $250.00  
Doxorubicin 9.8 8  $78.40  
Total Cost    $350.40  
Supportive Medicines 
A total of $4.64 is spent on chemotherapy-specific supportive medications for Wilms 
Tumor Patients (Table 8). 
Table 8: Supportive Medication Costs for Wilms Tumor Patients 
Drug Individual 
Dose in mg/m2 
Unit Price  
(in $US) 
# of units 
needed for full 
cycle 
Total Price 
(in $US) 
Ondansetron 4 0.11 16 1.76 
Metoclopramide 15 0.09 32 2.88 
TOTAL COST  $4.64  
Blood Products 
All blood products are provided free of charge to local hospitals through the National 
Center for Blood Transfusion Division (NCBT).  Assuming an average use of 5 RBC units 
(Red Blood Cell units available for transfusion) per patient over the treatment cycle, the cost 
per patient is $440. 
Radiotherapy Services 
Radiotherapy is provided through an agreement with Mulago Hospital in Uganda.  
The cost of accommodation and travel along with the medical bills for radiation and 
hospitalization are covered by the program.  Due to the lack of in-country treatment and the 
great expense, radiotherapy is only offered in limited circumstances and where cancer 
treatment intent is curative.  The average cost for one patient to receive radiotherapy 
during the time of the study was $3,133, including medical bills, accommodation and travel.  
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However, because only 4% of patients received this care, the cost per patient is significantly 
less when allocated across the patient population.  The resulting cost per patient is $120.51.  
Imaging and Surgical Costs  
CT Scans are conducted in the primary hospital in Kigali and supported by the 
Ministry of Health.  The patient is responsible for the cost of the CT Scans.  Imaging is 
covered by the Mutelle de Sante program; therefore, any patient with the community 
insurance will have 90% of the cost of their scan paid and will be responsible for the other 
10%.  For vulnerable patients, the oncology program will cover any costs not paid by 
insurance.  The cost to the Ministry is therefore typically 90% of the full cost of the scans. A 
CT Scan is recommended for the abdomen both pre- and post-treatment. According to the 
2012 Rwandan National Reference for Rates and Hospital Centres, the cost of the abdominal 
CT Scan is $141.08.  Transport from Butaro to Kigali is included at a cost of $13.23 per 
roundtrip.  The cost of surgery for a Wilms Tumor patient is $91.26.  The cost of 2 sets of 
CT Scans, surgery and transportation for each totals $384.90 per patient.   
Social Support Costs  
Transportation stipends are necessary to ensure a patient’s ability to complete a full 
course of treatment. The median round trip cost of transport is 8,200 RWF (approximately 
12 USD).  Assuming a patient with Wilms Tumor makes at least 24 trips to the Cancer 
Center (including 9 trips for pre-surgical chemotherapy, 11 trips for post-surgical 
chemotherapy and 4 follow up appointments), the resulting cost would be a total of $289 
for a full course of treatment. 
Labor 
Total labor costs for the treatment of Wilms Tumor were determined to be $414.64 
(Table 9).  Calculations included doctors, nurses, social workers, cashiers, intake 
coordinators, lab technicians and pharmacy staff.  We identified all relevant hospital staff 
that come in contact with the patient.  We then interviewed clinicians to determine the 
major activities performed in treating each type of cancer and created process maps to 
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estimate the amount of time each type of provider spends on each activity with each 
patient.  Staff salaries were adjusted by the estimated total number of paid hours actually 
worked each year to determine a cost per minute for each provider.  This was then 
multiplied by the time spent on the patient care activities identified to create a total staff 
cost per patient. Given the short duration of treatment, we did not apply a discount rate. 
Table 9:  Total Labor Cost for Wilms Tumor 
TREATMENT VISIT  Total Labor 
Cost  
Initial Visit  and Diagnosis (including week 1 chemo)  $32.96  
Week 2  $14.06  
Week 3  $15.05  
Week 4  $14.06  
Week 5  $23.88  
Week 6  $14.06  
Week 7  $15.05  
Week 8  $14.06  
Week 9  $23.88  
Surgery   
Week 1  $14.06  
Week 2  $23.88  
Week 3  $14.06  
Week 4  
Week 5  $23.88  
Week 6  $14.06  
Week 7  
Week 8  $23.88  
Week 9  $14.06  
Week 10  
Week 11  $23.88  
Week 12  $14.06  
Week 13  
Week 14  $23.88  
Week 15  $14.06  
Follow Up every 3 months for 1 year  $43.78  
TOTAL LABOR COSTS FOR A FULL COURSE OF TREATMENT  $414.64  
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Equipment and Supplies   
The total annualized per patient cost was calculated to be $26, including costs for 
cancer center construction and renovation, ambulance purchase and equipment and 
pathology equipment and supplies (Table 10).  Costs for equipment and supplies were 
distributed across all service-life years and adjusted from the annual to current costing 
year. 
Table 10: Annualized Cost per Wilms Tumor Patient 
Expenditure Category Total Cost in USD Total Annualized Cost in 
USD 
Pathology Lab and Equipment $100,848 $20,231 
Cancer Center Construction $327,815 $40,229 
Cancer Center Renovation Costs $25,461 $3,123 
Ambulance Purchase $16,970 $3,195 
Total Annualized Capital Costs  $66,779 
Total per Patient  $26 
Overhead 
The annual overhead costs for the oncology program (including sewage, electricity, 
plumbing, communications, training, security, and cleaning) was determined to be $5.37 
(Table 11).  A proportion of the total cost was assigned to each patient treated based on 
patient volume and time on the ward.  Calculations are based on a total of 40 hospital days 
over the course of treatment and follow-up.  (This calculation represents 12 hospital stays 
of 1 day; 8 hospital stays of 3 days and 4 follow up visits of 1 day.  Calculations for time on 
the ward were based on the established protocols combined with provider advice.  The 
estimate chosen is consistent with the average hospitalization time for a full course of 
treatment including one adverse event.) 
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Table 11: Cost of Overhead per Patient for Wilms Tumor 
Expenditure Category Total Cost in USD 
Overhead Cost/Patient/Day $0.13  
Total Days on the Ward expected 
per Wilms Patient 
40 
Total Overhead Cost per Patient $5.37 
Total Costs 
The total cost of treatment for a patient with metastatic Wilms Tumor was found to 
be $2,036 (Table 12).  Labor and blood products are the primary cost drivers, accounting 
for 21% and 22% of costs respectively.  Chemotherapy (17%) and CT scans and surgeries 
(19%) also account for large proportions of the overall cost. Transportation costs represent 
a significant proportion of the total cost (at 15%); however, it is important to note that 
these costs are based on the assumption that a patient will require transportation support 
for every trip over a full course of treatment and follow-up.  Radiotherapy represents only 
6% of the total cost due to the small proportion of patients receiving this treatment option.   
Capital costs, overhead and supportive care medications are all minimal costs at the patient 
level.  
Table 12: Total Cost of Treatment for Wilms Tumor by Category 
Cost Category Per Patient  Total Cost in USD  
Total annualized capital costs  $26  
Overhead  $5  
Chemotherapy  $350  
Supportive Care Meds  $5  
CT Scans, Surgery and 
Transport 
 $385  
Blood Products  $440  
Radiotherapy  $121  
Transportation Support  $289  
Labor  $415  
Total Cost/Patient  $2,036  
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Figure 2: Cost of Treatment for a Wilms Tumor Patient 
AIM #3: HODGKINS LYMPHOMA 
Our third study aim was to determine the cost of treating a child with Hodgkin Lymphoma at 
the Butaro Cancer Center of Excellence. We determined the cost of a full course of 
treatment for a child with Stage III Hodgkin Lymphoma (including diagnosis, treatment and 
follow-up) to be $1,744.  
Chemotherapy  
For a child with Stage III Hodgkin Lymphoma, a BSA of 1m2 and a weight of 30kg, 
the Rwandan protocol calls for 6 cycles of ABVD [Adriamycine (= Doxorubicine), 
Bleomycine, Vinblastine, and Dacarbazine] every 4 weeks. A full course of chemotherapy for 
this child will cost $514.20 (Table 13).   
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Table 13: Chemotherapy Costs per HL Patient 
Drug Unit Price  
(in $US) 
# of vials for full 
cycle 
Total Price  
(in $US) 
Doxorubicin  $9.80  12  $117.60  
Bleomycin  $10.25  12  $123.00  
Vinblastine  $5.80  12  $69.60  
Dacarbazine  $8.50  24  $204.00  
TOTAL COST    $514.20  
Supportive Medicines 
Medications supporting chemotherapy were determined to total $4.76 per patient 
(Table 14). 
Table 14: Supportive Medication Costs per HL Patient 
Drug Individual 
Dose in 
mg/m2 
Unit 
Price (in 
$US) 
# of vials 
needed for full 
cycle 
Total 
Price (in 
$US) 
Allopurinol 300 0.03 4 0.12 
Ondansetron 4 0.11 16 1.76 
Metoclopramide 15 0.09 32 2.88 
TOTAL COST  $4.76  
Blood Products 
All blood products are provided free of charge to local hospitals through the National 
Center for Blood Transfusion Division (NCBT).  Assuming an average use of 7 RBC units 
(Red Blood Cell units available for transfusion) per patient over the treatment cycle, the cost 
per patient is $616. 
Transportation Stipends  
Assuming a patient with Hodgkin Lymphoma makes at least 12 trips to the Cancer 
Center for treatment, the resulting cost would be a total of $144.60 to cover all 
transportation costs for a full course of treatment. 
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Labor Costs 
The cost of all staff involved of the treatment of pediatric cancer patients, including 
doctors, nurses, social workers, cashiers, lab techs, pathologists and nutritionists, was 
found to be $432.87.  During the time of the study all chemotherapy required 
hospitalization.  The initial hospital visit consists of a consultation, pathology analysis and 
diagnosis, and the initiation of chemotherapy over a 4-day period.  Return visits for 
chemotherapy occur every 15 days for 6 cycles of 2 days each and are followed by 10 
follow-up visits over 2 years.  Given the short duration of treatment, we did not apply a 
discount rate.  Table 15 below outlines the labor costs for each hospital stay.   
Table 15: Cost of Labor per Patient for HL 
Step Name Total Labor 
Cost  
Initial Visit (including ABVD Cycle 1, Day 1)  $37.08  
Pathology Processing  $5.22  
ABVD Cycle 1, Day 15  $22.56  
ABVD Cycle 2, Day 1  $22.56  
ABVD Cycle 2, Day 15  $22.56  
ABVD Cycle 3, Day 1  $23.73  
ABVD Cycle 3, Day 15  $23.73  
ABVD Cycle 4, Day 1  $23.73  
ABVD Cycle 4, Day 15  $23.73  
ABVD Cycle 5, Day 1  $23.73  
ABVD Cycle 5, Day 15  $23.73  
ABVD Cycle 6, Day 1  $23.73  
ABVD Cycle 6, Day 15  $23.73  
Follow Up 1 month after treatment ends for 6 months  $66.52  
Follow Up every 3 months for 1.5 years  $66.52  
TOTAL LABOR COSTS FOR A FULL COURSE OF TREATMENT  $432.87  
Equipment and Supplies   
A total annualized cost was calculated for construction, renovation, equipment and 
supplies related to the Butaro Cancer Center and adjusted by the number of active patients 
during the time period for a per patient cost of $26 (Table 16).  Costs for equipment and 
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supplies were distributed across all service-life years and adjusted from the annual to 
current costing year. 
Table 16:  Total Annualized Per Patient Cost for Equipment and Supplies 
Expenditure Category Total Cost in 
USD 
Total Annualized Cost in 
USD 
Pathology Lab and Equipment $100,848 $20,231 
Cancer Center Construction $327,815 $40,229 
Cancer Center Renovation Costs $25,461 $3,123 
Ambulance Purchase $16,970 $3,195 
Total Annualized Capital Costs  $66,779 
Total per Patient  $26 
Overhead 
A proportion of all annual overhead costs for the oncology program (including 
sewage, electricity, plumbing, communications, training, security, cleaning, etc.) was 
assigned to each patient treated based on patient volume and time on the ward.  Time on 
the ward was calculated assuming a total of 40 days over the course of treatment and 
follow-up.  (This represents 2 hospital stays of 4 days and 10 hospital stays of 2 days with 
12 follow up visits over 2 years.  Calculations for time on the ward were based on the 
established protocols combined with provider advice.  The estimate chosen is consistent 
with the average hospitalization time for a full course of treatment including one adverse 
event.)  Table 17 outlines the total cost of overhead per patient diagnosed with Hodgkin 
Lymphoma. 
Table 17: Overhead Costs per HL Patient 
Expenditure Category Total Cost in USD 
Overhead Cost/Patient/Day $0.13  
Total Days on the Ward expected per Patient 40 
Total Overhead Cost per Patient $5.37 
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Total Costs 
The total cost per patient with Hodgkin Lymphoma is estimated to be $1,744 (Table 
18).  This estimate is based on an idealized patient receiving the full course of treatment, 
follow up and recommended social support.  Blood Products and Chemotherapy are the 
primary cost drivers accounting for 35% and 30% of the total cost respectively.  Labor is 
also a significant cost driver at 25%.  Transportation is a less significant factor (at 8% of the 
total) in the treatment of Hodgkin Lymphoma than it was in the treatment of Wilms Tumor 
due to the fewer number of hospital trips required.  Figure 3 represents the proportion of 
costs by category. 
Table 18: Total Cost per HL Patient 
Cost Category Per Patient Total Cost in USD  
Total annualized capital costs  $26  
Overhead  $5  
Chemotherapy  $514  
Supportive Care Meds  $5  
Blood Products  $616  
Transportation Support  $145  
Labor  $433  
Total Cost/Patient  $1,744  
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Figure 3: Cost of Treatment for a HL Patient 
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CHAPTER SIX:  FORECASTING FUTURE COSTS 
SCENARIO ANALYSIS 
Our analysis reflects program costs during the initial phases of the program, and in 
fact, in the very first years of its development.  As a result, many of the costs are reflective 
of expenses expected during ramp-up of a program but not necessarily full program 
implementation.  Once the program is fully functional, costs are likely to be lower due to 
greater efficiencies of scale and greater local capacity.  For example, this analysis was 
conducted at a time when all chemotherapy was delivered on an inpatient basis.  In 
subsequent years, the construction of an infusion center has allowed patients to receive 
chemotherapy on an outpatient basis improving efficiency of staff and lowering the number 
of hospital days required for treatment. 
In order to effectively project future costs, we conducted a scenario analysis to 
model the potential effects of changes in key variables on the annual cost of running the 
cancer program.  Three scenarios were constructed to help administrators plan and budget 
for future program growth and expansion.  Each scenario examines the outcomes of 
changes in major variables such as drug prices, availability of volunteer providers, and 
patient volume.  
The first, a worse case scenario, assumed no growth in patient volume and no 
greater efficiencies of scale.  This scenario also assumed that the current labor provided for 
free to the program would no longer be available and replacement salaries for Rwandan 
providers would need to be paid for in full by the program.  All other variables remained 
constant. 
The second scenario reflects our best estimate of the most likely scenario.  This 
scenario assumes that patient volume continues to increase steadily over the next several 
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years reaching a steady state projection of 2,064 new patients per year. This scenario is 
consistent with approximately 60% of expected new cancer cases being treated at the 
Butaro Cancer Center of Excellence, which is currently the only source of free cancer care in 
the country.  The scenario assumes that chemotherapy and supportive medications and 
treatment services scale in keeping with the 60% increase in patient volume.  New paid 
positions will cover some of the increase in patient volume, while volunteer labor is 
projected to remain available to cover the remaining volume increase.  Staff costs will 
increase slightly as pathology is now projected to be handled in house.  Pathology shipping, 
duties and fees will also be reduced due to the switch to local pathology services.   
The final scenario reflects the best case scenario.  This scenario assumes that the 
patient volume reached in scenario 2 is the steady state for the oncology program, despite 
the addition of a new cancer care facility in another region of the country.  The third 
scenario also includes a reduction of 30% in the cost of chemotherapy medications.  This 
reduction could be possible as a result of greater negotiating power due to increased patient 
volume.  The best case scenario also projects reductions of 50% in the social support costs 
related to patient travel.  Because the Butaro Cancer Center is located in a remote region; 
the average cost of transportation support is high.  If another more central location was 
constructed, transportation costs could be expected to drop significantly for that center as 
fewer patients will be traveling and those that do will not need to travel as far to receive 
care. 
Table 19 below compares the outcomes of each of the 3 scenarios.  The analysis 
expects annual program costs to level out at approximately $644/patient in the most likely 
case scenario for the steady state projection.  While projected costs are higher for the likely 
scenario than for the worst case scenario, there is greater efficiency of care resulting in a 
much lower average cost per patient.  The average cost per patient drops even lower in the 
best case scenario to $615.  Even in the worst case scenario, the average cost per patient of 
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$777 is much lower than would be expected based on the costs seen in high and middle 
income countries. 
Table 19: Scenario Analysis for the Oncology Program 
  Worst Case 
Scenario 
Most Likely 
Scenario at 2064 
new patients/year 
Best Case 
Scenario 
Overhead   $65,714   $65,714   $65,714  
Training  $60,434   $60,434   $60,434  
Chemo and Supportive Med 
Procurement 
 $139,134   $222,614   $178,092  
Non-Chemotherapy Related 
Medications and Consumables 
 $40,456   $64,730   $64,730  
Pathology   $58,190   $42,860   $42,860  
Radiotherapy  $236,844   $378,950   $378,950  
Blood Products  $59,730   $95,568   $95,568  
CT Scans and Surgeries  $75,125   $120,200   $120,200  
Social Services  $21,117   $33,787   $16,894  
Labor  $245,217   $245,217   $245,217  
Total Program Cost $1,001,961   $1,330,075  $1,268,658  
Cost/Newly Enrolled Patient  $777   $644   $615  
COSTS PER PATIENT 
The current cost per patient diagnosed with Wilms Tumor is based on a Stage III 
patient completing a full cycle of treatment and follow-up. Of course, in a real world setting 
not all patients will present at the same stage, have the same disease progression or 
complete treatment and/or follow-up.  If you assume that outcomes continue to be similar 
to the initial outcomes seen in Rwanda for Wilms patients49, you would expect that: 
 7% of patients present at late stages and die prior to commencing chemotherapy 
 30% of patients begin chemotherapy but are lost prior to surgery (either due to  
 loss to follow up or death) 
 9% are lost after surgery  
 11% are lost during the last phase of treatment 
 4% complete treatment but are lost to follow-up  
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 39% complete both treatment and follow-up 
Assuming these outcomes, the adjusted average cost per patient would be 
considerably less:  $1,420 per patient.  Therefore, the range of costs to treat a patient with 
Wilms Tumor is quite large, ranging from a high of $2,036 down to a low of $1,420 per 
patient.  The cost of $2,036 represents the idealized cost of treating a patient with Wilms 
Tumor assuming the patient receives a full course of treatment and follow-up as well as all 
necessary social support; whereas $1,420 is the per patient cost adjusted for expected 
survival and loss to follow up outcomes.  The analysis assumes one adverse event but does 
not take into account treatment of a potential relapse. 
While we do not yet have initial outcome data for patients treated with Hodgkin 
Lymphoma at the Butaro Cancer Center, if we can assume a roughly similar proportion of 
patients complete each stage of treatment, we would expect to see: 
 10% of patients present at late stages and die prior to commencing chemotherapy 
 30% of patients are lost prior to the completion of Cycle 3 
 17% are lost prior to Cycle 6 
 4% complete treatment but are lost to follow-up  
 39% complete both treatment and follow-up 
The total cost of treatment per patient adjusting for expected survival and loss to 
follow up was estimated to be $1,147 per patient, representing a reduction of $595 per 
patient. 
53 
CHAPTER SEVEN:  DISCUSSION  
SUMMARY OF KEY FINDINGS 
The overall cost of the cancer program for the 2013-2014 fiscal year was estimated 
at $911,699 with an additional $556,105 needed for start-up activities. This represents the 
cost of treating 1,290 new patients and an additional 1,286 existing patients during the 
study period.  This study is one of the first to examine overall program costs for ramp-up 
and implementation of a cancer center in a low income country.  The results are useful in 
considering costs and cost-drivers when establishing new cancer facilities in Rwanda and 
beyond.  The experience of the Butaro Cancer Center makes a strong case for the 
affordability of cancer care in low income settings.  By combining a strong commitment to 
cancer control, adaptation of protocols to the local context, task shifting and collaborative 
partnerships, the Butaro Cancer Center of Excellence has been able to effectively maximize 
resources while minimizing costs.  Cost-effectiveness research will be needed when outcome 
data become available; however, this study clearly shows that quality cancer care is 
possible at a fraction of the cost of treating cancer in middle and high income countries.   
Over the course of the study period 1,290 newly enrolled cancer patients were 
treated at the Butaro Cancer Center of Excellence with an average cost per patient across 
cancer diagnoses of $777.  The study represents costs during the initial years of 
development during the ramp-up phase of the center.  Our analysis projects that costs 
could decrease to an average of $615 per patient over time as patient volume increases and 
efficiencies of scale are realized.  
The cost for a full course of treatment and follow-up was determined to be $2,036 
for a patient with Wilms Tumor.  Adjusting for expected survival rates and loss to follow-up, 
the cost per patient decreases to $1,432.  The cost for a full course of treatment for a 
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pediatric patient with Hodgkin Lymphoma was determined to be between $1,147 and 
$1,744.  The cost per patient can seem expensive in a country where the GDP per capita is 
$639 US.50  However, it is important to consider that the average cost of a full course of 
chemotherapy per patient in the United States has been estimated to be between $20,000 
and $100,000 depending on cancer type51.  Despite the United States GDP per capita of 
$54,000, few would argue that cancer is too expensive to treat or that cancer patients 
should go without access to care.    
The cost of treatment determined in this study is much less than the cost of care 
enumerated in mid and high income settings. While costing data for pediatric cancer care is 
limited, the literature review identified several studies examining treatment costs for ALL 
ranging from a low of approximately $11,000 per patient in middle income countries to a 
high of around $100,00 in high income countries.  Given ALL’s longer treatment period and 
more complex disease progression, we would expect to see higher costs for ALL treatment 
in Rwanda as well; although costs are still not likely to be as high as those seen in middle 
income countries due to differences in labor costs, drug prices and service cost between 
countries.  A study conducted in 2 South African hospitals found the total cost of diagnosing, 
staging and treating a child with Hodgkin Lymphoma to be $6,647.27.  Here again, our 
analysis found a much lower cost per patient.  Drug prices reflect a large portion of the 
difference – in Rwanda the course of chemotherapy is approximately one-fifth of the cost 
outlined in the South African study.  Similarly, CT Scans and radiotherapy were included as 
standard components of treatment in the South African study but were not standard 
components in the Rwandan analysis. 
There are a number of other factors responsible for the discrepancies seen between 
the costs of care in low, middle and high income countries.  As with many developing 
countries, the cost of labor for the cancer center is significantly less expensive than in more 
economically developed countries.  In addition, Rwanda utilizes a task-shifting model to 
allow generalists (pediatricians, internists and general practitioners) to provide care with weekly 
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structured phone support from US-based oncologists.  This further reduces the cost of providing care.  
Consider that the labor costs for the entire cancer center (including all positions from 
doctors, nurses, and nutritionists to janitors and cashiers) is less than the average annual 
salary of $217,857 for one oncologist in the United States.  In addition, local protocols 
intended to reduce toxicity and length of treatment also often reduce the costs of care.  
Finally, expensive treatment modalities such as radiotherapy which are common in higher 
income settings are limited to those most in need where resources are scarce. 
By 2020, the number of children with cancer is expected to increase by more than 
thirty percent.  Ninety percent of the world’s children live in developing countries; thus the 
majority of new pediatric cancer cases will be occurring in countries that are the least 
equipped to respond to the growing burden.    Rwanda’s commitment to cancer care is all 
the more important given this alarming trend.  The analysis clearly shows that quality 
cancer care can be achieved at a fraction of the cost of care in high income countries. 
LIMITATIONS 
Perspective 
The study is limited by the perspective of the analysis.  Our focus was on capturing 
the costs of implementing an effective cancer program and did not include the larger 
societal costs of treatment, such as the out-of-pocket expenses of patients or lost 
productivity during treatment.  Patients receiving care at the Butaro Cancer Center often 
travel long distances and are required to be away from home for long periods of time.  An 
analysis of societal costs should include not only the time the patient spends away from 
school and home but also the lost productivity of the parent who must accompany the 
patient, losing time away from work and other family members.  The cost of treatment for 
the family and society as a whole can be significant but is not reflected in this study. 
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Treatment Protocol   
The cost per patient was determined using an idealized patient receiving a full course 
of treatment and follow-up in accordance with the current Rwandan protocol for treatment 
of each cancer.  Protocols for childhood cancer treatment created and refined in high income 
countries do not necessarily represent the best quality of care in low resource settings.  
Often, the complexity, toxicity, and length of treatment combined with the availability of 
resources can profoundly affect the effectiveness of these protocols. As a result, protocols 
need to be adapted to local contexts. Because the Butaro Cancer Center is a relatively new 
program, the protocols for these (and other) cancers are in the early stages of adaptation to 
the local context.  As the recommended protocols are further refined, we can expect to see 
corresponding changes in the cost of treatment.  For example, if radiotherapy is no longer 
recommended for patients with Wilms Tumor, we would expect to see a reduction in the per 
person cost of $120.51.  Further, it is likely that the methodology underestimates costs 
related to relapse as the methodology assumes a full course of successful treatment.   
Methodology and Data Constraints 
A number of data points were restricted or unavailable. The limitations in the 
methodology for each cost category are noted below.  We conducted a one-way sensitivity 
analysis to determine the parameters most likely to affect the cost per patient (Table 20).   
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Table 20: Sensitivity Analysis for the per Patient Costs of Treating Pediatric Cancer 
Cost Category  Total Revised Cost per Patient  % Change 
Labor Cost  +20%  $2,119  4% 
Labor Cost  -20%  $1,963  -4% 
Chemotherapy +20%  $2,106  3% 
Chemotherapy -20%  $1,966  -3% 
Blood Products +20%  $2,124  4% 
Blood Products -20%  $1,948  -4% 
CT Scans +20%  $2,113  4% 
CT Scans -20%  $1,959  -4% 
# of Patients - +20%  $2,031  0% 
# of Patients - -20%  $2,044  0% 
# of hospital days 
+50% 
 $2,019  -1% 
# of hospital days -
50% 
 $2,014  -1% 
Radiotherapy +50%  $2,097  3% 
Radiotherapy -50%  $1,976  -3% 
 
None of the parameters had a significant impact on the overall cost of care.  The 
parameters most sensitive to change include the cost of labor, blood products and CT Scans 
(each at 4%).  Increasing or decreasing the cost of chemotherapy by 20% resulted in a 3% 
change to the overall cost per patient.  Our analysis reflects only a minimal reduction in 
prices (20%), but given the magnitude of this parameter, if large reductions in the cost of 
chemotherapy drugs were achieved (such as those seen in other diseases of up to 95%), we 
could expect significant reductions in the overall price per patient.  Even with a change of 
50%, radiotherapy costs produced only a 3% change in the overall cost per patient.  This is 
due to the small number of patients (4%) currently receiving radiotherapy; if the protocol 
was adjusted and a large number of patients received radiotherapy, we would expect 
significant changes in this cost component.  Changes in the number of patients will have a 
substantial effect on both the cost of overhead and on the annualized equipment costs; 
however, since each of these costs contributes minimally to the cost of treating the patient, 
the overall effect on the cost per patient is minimal.  Similarly, while changes in the number 
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of days on the ward impact overhead, equipment and supplies, and labor, even large 
changes in the number of days have minimal effects (1% or less) on the overall per patient 
cost.  We analyzed the expected change in the number of days by 50% to reflect either the 
significant reductions in hospital days that would be expected when moving to an outpatient 
infusion center or the increase in the number of days if a patient were to have many 
additional adverse events.  
CT Scan Costs: The estimate for CT Scans and Surgeries for the program costs 
presented in Aim 1 was based on the total price paid by the oncology program to the 
primary hospitals in Kigali.  This price provides a good estimate as to the price paid by the 
implementing agency but is not useful in understanding the overall cost of the procedures 
from the Ministry perspective, as the estimate does not reflect the true cost of providing 
these services.  The costs covered by the program can represent anywhere between 10% 
and 100% per patient.  A full hard-copy invoice review across all cancer types from the 
CHUK and RHM systems was outside the scope of this study; however, this type of review 
would provide a better estimate of the full cost of these services from the Ministry 
perspective. 
Similarly, the per patient costs of CT Scans and Surgery in our analysis are based on 
the prices charged by the hospital to treat patients at coordinating hospitals.  We did not 
have access to the data necessary to do a full and accurate accounting of the costs of these 
procedures based on resource consumption.  Because a relatively small percentage of 
patients receive these services, this cost has limited sensitivity (4%).  However, a more 
accurate cost of these procedures would further refine our estimates. 
Blood Products: We did not have access to blood product usage during the study 
period; therefore, the average monthly utilization of blood products was estimated using 6 
months of usage over 2015-2016.  This could lead to higher cost estimates due to patient 
volume. Future studies will have access to order tracking and will be able to offer a more 
accurate assessment of costs. 
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Non-chemotherapy related medications and consumables:  We were able to attribute 
chemotherapy and supportive care medications directly to cancer to the cancer program; 
however, the use of general medications (such as ibuprofen and morphine) or consumables 
unrelated to chemotherapy (such as gloves) were not associated directly with the program.  
We had access electronically to one quarter of stock purchases for the pharmacy for such 
items and extrapolated to get a yearly cost and then attributed to the cancer program on 
the basis of beds.  This was our best available methodology given the data but likely 
overstates the cost of these medications and consumables to the cancer program.  Cancer 
medications were not included in the quarterly order, but other condition-specific 
medications were.  As a result, it is likely the estimate includes many drugs and supplies 
that are not relevant to the cancer program.  However, since the cost of non-chemotherapy-
related medications and consumables reflect only a small amount of the overall total (5%), 
the effect of this overage is minimal. 
Labor Costs: Labor costs were determined using provider interviews to estimate time 
spent on each activity related to patient care.  As a result, estimates are subject to recall 
bias as providers may not accurately remember or be able to estimate average time spent 
on each activity.  Multiple providers’ opinions were sought to minimize this bias as much as 
possible; however, room for error still exists. 
In addition, the Butaro Cancer Center relies heavily on volunteer labor (and 
particularly so during the ramp-up stage of development).  This free labor includes multiple 
volunteer doctors, nurses, social workers and pathologists.  Providers either volunteer their 
time or are reimbursed by their home institution with no cost to the cancer program or the 
Ministry of Health.   As a regular source of free labor has traditionally been available and will 
likely continue to be available in the future (from either the same or different sources), the 
cost of these volunteer services was not included in the analysis of program costs.  The 
scenario analysis above provides a basis for us to understand what the cost of running the 
program would be if volunteer staff must be paid.  However, the cost per patient assumes 
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that all providers are paid staff and does not take into account free labor.  Therefore, this 
methodology likely overstates the true cost per patient, as volunteer providers will also be 
providing care to individual patients. 
CONCLUSION 
The cancer burden in low-income countries is continuing to grow.  And yet, only 5% 
of the world’s resources to fight cancer are spent in low and middle income countries. 7 This 
lack of investment is deeply troubling when coupled with the fact that in the poorest 25 
countries of the world, an estimated 90% of children with cancer will die.  The example of 
the Butaro Cancer Center of Excellence provides a reason for optimism in the fight against 
cancer.  Studies such as this one help to increase our understanding of the affordability of 
cancer care in low income countries.  As the program grows and outcome data become 
available, a cost-effectiveness analysis would help us further understand the gain in health 
outcomes as they relate to the investment necessary for treating pediatric cancer in these 
countries.    
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CHAPTER EIGHT:  PLAN FOR CHANGE 
The results of the costing analysis will allow us to plan for greater capacity in 
Rwanda, to develop strategies to reduce the cost of curative cancer care and to advocate for 
appropriate resources to address the health inequities currently present in global cancer 
control.   By quantifying the cost of developing an effective cancer program, the advocacy 
community can better convey that cancer treatment costs in low income countries are not 
insurmountable.  Further, in outlining the components of cost in treating a child with cancer, 
we are able to facilitate the development of advocacy strategies for price negotiation and 
greater access to care.  These changes can be implemented both at the local level in 
Rwanda and globally through multi-national advocacy movements.  The strategies below 
represent the primary avenues for affecting change through the results of this study and 
beyond. 
NATIONAL CANCER CONTROL PLANNING 
National Comprehensive Cancer Control Plans create a blueprint for a country “to 
reduce cancer incidence and mortality and improve the quality of life of cancer patients, 
through the systematic and equitable implementation of evidence-based strategies for 
prevention, early detection, diagnosis, treatment and palliation, making the best use of 
available resources”.52  Such plans allow countries to create common goals and focus 
resources where they are most effective.  The Rwandan Ministry of Health is currently 
building a national cancer control plan.  As the planning has progressed, cost has remained 
an unknown - yet determining factor - for the further development of activities. A full 
understanding of the current costs and cost drivers will be helpful in prioritizing future 
investments. The costing analysis will be used in the planning process for the cancer plan to 
help inform Ministry of Health planning.  We will produce an overview presentation for 
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hospital administrators and cancer control planners to quickly and easily highlight core costs 
and projections.  We will also create a forecasting spreadsheet with built in modeling 
equations so that patient volume can be easily entered and scenario projections can be 
easily assessed.  These tools will make it easier to use the findings of the study within the 
planning process. 
CAPACITY BUILDING FOR CANCER CARE IN RWANDA 
The methodology was constructed to aid in forecasting future growth of the program. 
We are working with program administrators to ensure the outcomes can inform program 
planning and budget preparation. Program administrators are considering both the scale up 
of the Butaro facility as well as the creation of additional sites.  The methodology was 
constructed to provide the best platform possible to test out the cost implications of 
different scenarios.  In addition, plans are underway to adapt the methodology applied to 
Wilms Tumor and Hodgkin Lymphoma to determining the per patient cost of treating breast 
cancer.  As more outcome studies are initiated, we will build on the costing framework so 
that a costing perspective can be incorporated into additional research studies across other 
cancer types.   
IMPROVED ACCESS TO RADIOTHERAPY SERVICES  
The actual and expected costs enumerated for radiotherapy services make a strong 
case for the development of local radiotherapy capacity in Rwanda. Radiotherapy has been 
estimated to lead to a cure in 40% of patients, “compared to 49% of patients being cured 
by surgery, and 11% of patients by systemic treatments”.53   Radiotherapy capacity is 
extremely limited in low income countries - with no radiotherapy units at all located in 
Rwanda.  The initial investment for a basic radiotherapy clinic with two megavoltage units is 
estimated to be between 5 and 6 million USD.  This estimate includes the building, 
equipment and human resources necessary to run the equipment.  This is a hefty up front 
investment, but when amortized over the life of the clinic, the resultant cost is expected to 
be between $250,000 and $400,000 annually.54 
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The annual cost of providing radiotherapy services through the collaboration with the 
Mulago Hospital in Uganda was estimated to be between $237,000 and $308,000. Rwanda’s 
existing investment in radiotherapy is already close to the estimated annual investment for 
local capacity.  With local radiotherapy services, a much higher number of patients could 
receive treatment than are currently receiving care for the existing investment.  However, it 
will be important to consider additional on-going costs such as maintenance, quality control 
and staff training when evaluating this investment. 
The International Atomic Energy Association (IAEA) is a natural potential partner.  In 
2004 the IAEA established the Programme of Action for Cancer Therapy (PACT) to build 
global partnerships and assist low and middle income member states in developing and 
implementing radiation medicine capabilities. Over the last 40 years, the IAEA has invested 
over 250 million USD in developing radiotherapy programs for cancer care.54  We 
recommend working with PACT to integrate radiotherapy services into the current Rwandan 
cancer control strategy.  The need for radiotherapy services in low income countries is great 
and resources are limited; however, Rwanda's existing investment and capacity in providing 
cancer care should position the country as a strong partner, ready to implement.  
The current investment in radiotherapy comprises 26% of the overall program costs, 
but only a fraction of those in need are treated due to the great expense.  The IEAE 
recommends that each machine treat 500 patients per year.  Given the current scope and 
expected growth of the cancer burden in Rwanda, the country could expect to easily meet 
the recommended usage immediately and progress to a cost-effective threshold in a short 
amount of time. 
Establishing a partnership with PACT would create a net gain for the Rwandan 
program by providing the potential for significantly more curative care with minimal 
additional investment.  Greater survival rates can also contribute to greater economic 
output for those cured, in many cases returning the investment to the government within a 
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matter of years.54  The results of this study will be used to approach PACT and make the 
case for greater investment in radiotherapy services in Rwanda. 
DRUG PRICE NEGOTIATION   
This study has illuminated the components of cost allowing us to focus on those cost-
reduction strategies most likely to impact the overall cost of delivering cancer care.  For 
example, as chemotherapy medications account for 15% of the overall financial cost of 
treatment, efforts to procure chemotherapy drugs at reduced cost should to be prioritized.  
Changes in drug pricing could be easily adapted within the model to forecast how shifts in 
drug pricing could affect the cost per patient for treatment.  The PIH procurement team use 
the results for ongoing pricing negotiation and advocacy efforts.  
NEXT STEPS 
In order to facilitate the utility of these findings, I will take the following immediate 
actions: 
1. Develop and share overview tools to present findings in settings with multiple 
stakeholders:  I will create an overview presentation to share the results of the 
study that can be used in future planning efforts and advocacy settings. I will 
share the findings with the cancer advocacy community where possible to 
encourage stakeholders and advocates to share the message of the cost of 
cancer treatment. 
2. Create cost forecasting tools:  I will create a forecasting spreadsheet with built in 
modeling equations so that patient volume can be adjusted and scenario 
projections can be assessed.  This tool will allow planners to more easily adapt 
and use the findings within the planning process. 
3. Publish:  We plan to publish several papers resulting from this work so as to 
ensure wider availability of information as well as to inform and spur future 
research. 
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